A detailed history of Royal Bank Of Canada transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,833 shares of CADL stock, worth $24,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,833
Previous 2,264 25.13%
Holding current value
$24,788
Previous $14,000 35.71%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.02 - $7.76 $2,856 - $4,415
569 Added 25.13%
2,833 $19,000
Q2 2024

Aug 14, 2024

BUY
$1.68 - $14.0 $3,687 - $30,730
2,195 Added 3181.16%
2,264 $14,000
Q1 2024

Nov 05, 2024

SELL
$1.21 - $1.86 $2,655 - $4,082
-2,195 Reduced 96.95%
69 $0
Q1 2024

May 15, 2024

BUY
$1.21 - $1.86 $47 - $72
39 Added 130.0%
69 $0
Q4 2023

Feb 14, 2024

SELL
$0.68 - $1.47 $187 - $405
-276 Reduced 90.2%
30 $0
Q3 2023

Nov 14, 2023

BUY
$0.91 - $1.3 $130 - $185
143 Added 87.73%
306 $0
Q2 2023

Aug 14, 2023

BUY
$1.2 - $1.78 $195 - $290
163 New
163 $0

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $253M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.